CO6382157A2 - Compuestos pirazina como inhibidores de fosfodiesterasa 10 - Google Patents
Compuestos pirazina como inhibidores de fosfodiesterasa 10Info
- Publication number
- CO6382157A2 CO6382157A2 CO11073978A CO11073978A CO6382157A2 CO 6382157 A2 CO6382157 A2 CO 6382157A2 CO 11073978 A CO11073978 A CO 11073978A CO 11073978 A CO11073978 A CO 11073978A CO 6382157 A2 CO6382157 A2 CO 6382157A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- pirazina
- phosphodesterase
- inhibitors
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos pirazina, y composiciones que las contienen, y procesos para preparar tales compuestos. En la presente también se proporcionan métodos para tratar trastornos o enfermedades tratables por inhibición de PDE10, tales como obesidad, diabetes no dependiente de insulina, esquizofrenia, trastorno bipoIar, trastorno obsesivo-compuesto, y similares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11456708P | 2008-11-14 | 2008-11-14 | |
| US16621209P | 2009-04-02 | 2009-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6382157A2 true CO6382157A2 (es) | 2012-02-15 |
Family
ID=41478512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11073978A CO6382157A2 (es) | 2008-11-14 | 2011-06-14 | Compuestos pirazina como inhibidores de fosfodiesterasa 10 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US8053438B2 (es) |
| EP (1) | EP2364308B1 (es) |
| JP (1) | JP5746972B2 (es) |
| KR (1) | KR20110083746A (es) |
| CN (1) | CN102300860B (es) |
| AR (1) | AR074358A1 (es) |
| AU (1) | AU2009313768B2 (es) |
| BR (1) | BRPI0922095A2 (es) |
| CA (1) | CA2742993C (es) |
| CL (1) | CL2011001094A1 (es) |
| CO (1) | CO6382157A2 (es) |
| CR (1) | CR20110326A (es) |
| CY (1) | CY1113680T1 (es) |
| DK (1) | DK2364308T3 (es) |
| EA (1) | EA019206B1 (es) |
| ES (1) | ES2397218T3 (es) |
| HK (1) | HK1161251A1 (es) |
| HR (1) | HRP20130054T1 (es) |
| IL (1) | IL212687A0 (es) |
| MA (1) | MA32889B1 (es) |
| MX (1) | MX2011005100A (es) |
| NZ (1) | NZ592508A (es) |
| PE (1) | PE20110581A1 (es) |
| PL (1) | PL2364308T3 (es) |
| PT (1) | PT2364308E (es) |
| RS (1) | RS52598B (es) |
| SI (1) | SI2364308T1 (es) |
| SM (1) | SMT201200061B (es) |
| TN (1) | TN2011000221A1 (es) |
| TW (1) | TWI396689B (es) |
| WO (1) | WO2010057121A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| JP2012512255A (ja) * | 2008-12-17 | 2012-05-31 | アムジエン・インコーポレーテツド | ホスホジエステラーゼ１０阻害剤としてのアミノピリジンおよびカルボキシピリジン化合物 |
| HUE027478T2 (en) | 2009-02-05 | 2016-09-28 | Takeda Pharmaceuticals Co | Pyridazinone Compounds |
| JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用 |
| KR101830447B1 (ko) * | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도 |
| SG183321A1 (en) | 2010-02-19 | 2012-09-27 | Boehringer Ingelheim Int | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| TWI546302B (zh) | 2010-06-24 | 2016-08-21 | 武田藥品工業股份有限公司 | 稠合雜環化合物 |
| EP2602255B1 (en) | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| EP2601192B1 (en) | 2010-08-04 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| JP5800814B2 (ja) | 2010-08-10 | 2015-10-28 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| RU2632900C2 (ru) | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| CN103619841B (zh) | 2011-01-11 | 2017-03-29 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
| EP2687529B1 (en) | 2011-03-16 | 2016-07-13 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| TWI570122B (zh) | 2011-06-22 | 2017-02-11 | 武田藥品工業股份有限公司 | 稠合雜環化合物之結晶 |
| CA2922849A1 (en) * | 2012-08-31 | 2014-03-06 | Ixchel Pharma, Llc | Agents useful for treating obesity, diabetes and related disorders |
| CN102911135B (zh) * | 2012-10-18 | 2016-01-13 | 内蒙古工业大学 | 2-巯基苯并噻唑类衍生物的合成方法 |
| AU2014215478B2 (en) | 2013-02-05 | 2018-09-13 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| EP2975037A4 (en) | 2013-03-15 | 2016-08-10 | Daiichi Sankyo Co Ltd | BENZOTHIOPHENE DERIVATIVE |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| RU2016110852A (ru) | 2013-09-27 | 2017-10-30 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| CN104649882A (zh) * | 2015-02-11 | 2015-05-27 | 南通恒盛精细化工有限公司 | 一种磷酸二酯酶抑制剂的中间体制备工艺 |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| CN108290838B (zh) * | 2015-09-18 | 2021-12-31 | 科研制药株式会社 | 双芳基衍生物和含有其的药物 |
| WO2019141259A1 (zh) * | 2018-01-19 | 2019-07-25 | 苏州信诺维医药科技有限公司 | 杂环化合物、制备方法及其在医药上的应用 |
| CN109020977B (zh) * | 2018-10-26 | 2020-11-13 | 安庆奇创药业有限公司 | 一种Acalabrutinib的制备方法 |
| JP2023553699A (ja) | 2020-12-17 | 2023-12-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヘテロ芳香族イソチオシアネート類 |
| CN113929598A (zh) * | 2021-11-24 | 2022-01-14 | 上海吉奉生物科技有限公司 | 一种（s）-2-叔丁氧羰基氨基-3-（4,4-二氟环己基）丙酸的合成方法 |
| CN117024405A (zh) * | 2022-05-09 | 2023-11-10 | 浙江同源康医药股份有限公司 | 多环类化合物及其用途 |
| CN115894181A (zh) * | 2022-09-30 | 2023-04-04 | 渭南高新区海泰新型电子材料有限责任公司 | 一种环己烯基环己基二氟苯类液晶化合物的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198417A (en) | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
| ATE392896T1 (de) | 2003-04-04 | 2008-05-15 | Lundbeck & Co As H | 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6- tetrahydropyridin-derivate als serotonin- wiederaufnahme-hemmer |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| DE10344223A1 (de) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| NZ551017A (en) * | 2004-05-18 | 2010-11-26 | Schering Corp | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors |
| US20090162286A1 (en) * | 2004-06-07 | 2009-06-25 | Pfizer Inc. | Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| RU2008107868A (ru) | 2005-08-02 | 2009-09-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве ингибиторов протеинкиназ |
| AU2007217750A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| US20090176829A1 (en) * | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| CA2673435C (en) * | 2006-12-21 | 2012-10-09 | Pfizer Products Inc. | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
| KR20100089090A (ko) | 2007-10-25 | 2010-08-11 | 아스트라제네카 아베 | 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체 |
| WO2009081259A1 (en) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
| WO2010008739A2 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
-
2009
- 2009-11-13 TW TW098138718A patent/TWI396689B/zh not_active IP Right Cessation
- 2009-11-16 SI SI200930429T patent/SI2364308T1/sl unknown
- 2009-11-16 AU AU2009313768A patent/AU2009313768B2/en not_active Ceased
- 2009-11-16 PT PT97527055T patent/PT2364308E/pt unknown
- 2009-11-16 EP EP09752705A patent/EP2364308B1/en active Active
- 2009-11-16 US US12/619,574 patent/US8053438B2/en not_active Expired - Fee Related
- 2009-11-16 WO PCT/US2009/064637 patent/WO2010057121A1/en active Application Filing
- 2009-11-16 CN CN200980154871.6A patent/CN102300860B/zh not_active Expired - Fee Related
- 2009-11-16 ES ES09752705T patent/ES2397218T3/es active Active
- 2009-11-16 KR KR1020117013506A patent/KR20110083746A/ko not_active Application Discontinuation
- 2009-11-16 BR BRPI0922095A patent/BRPI0922095A2/pt not_active IP Right Cessation
- 2009-11-16 DK DK09752705.5T patent/DK2364308T3/da active
- 2009-11-16 CA CA2742993A patent/CA2742993C/en not_active Expired - Fee Related
- 2009-11-16 EA EA201100748A patent/EA019206B1/ru not_active IP Right Cessation
- 2009-11-16 JP JP2011536567A patent/JP5746972B2/ja not_active Expired - Fee Related
- 2009-11-16 PL PL09752705T patent/PL2364308T3/pl unknown
- 2009-11-16 NZ NZ592508A patent/NZ592508A/xx not_active IP Right Cessation
- 2009-11-16 PE PE2011001035A patent/PE20110581A1/es not_active Application Discontinuation
- 2009-11-16 RS RS20120569A patent/RS52598B/en unknown
- 2009-11-16 MX MX2011005100A patent/MX2011005100A/es active IP Right Grant
- 2009-11-16 AR ARP090104436A patent/AR074358A1/es not_active Application Discontinuation
-
2011
- 2011-03-07 US US13/042,410 patent/US8329700B2/en not_active Expired - Fee Related
- 2011-03-07 US US13/042,421 patent/US8247418B2/en not_active Expired - Fee Related
- 2011-05-04 IL IL212687A patent/IL212687A0/en unknown
- 2011-05-05 TN TN2011000221A patent/TN2011000221A1/fr unknown
- 2011-05-13 CL CL2011001094A patent/CL2011001094A1/es unknown
- 2011-06-10 MA MA33928A patent/MA32889B1/fr unknown
- 2011-06-14 CR CR20110326A patent/CR20110326A/es not_active Application Discontinuation
- 2011-06-14 CO CO11073978A patent/CO6382157A2/es not_active Application Discontinuation
-
2012
- 2012-02-27 HK HK12101965.5A patent/HK1161251A1/xx not_active IP Right Cessation
- 2012-06-22 US US13/531,453 patent/US20120277209A1/en not_active Abandoned
- 2012-12-19 SM SM201200061T patent/SMT201200061B/it unknown
- 2012-12-21 CY CY20121101246T patent/CY1113680T1/el unknown
-
2013
- 2013-01-22 HR HRP20130054AT patent/HRP20130054T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6382157A2 (es) | Compuestos pirazina como inhibidores de fosfodiesterasa 10 | |
| CO6630189A2 (es) | Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10 | |
| CR20110103A (es) | Heteroarilos sustituidos | |
| TN2011000220A1 (en) | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | |
| CO6430427A2 (es) | Derivados de benzofuranilo | |
| HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| ECSP088210A (es) | Bencimidazoles sustituidos y métodos de preparación | |
| CR20110077A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
| TN2011000279A1 (en) | Novel pyrazole -4-n-alkoxycarboxamides as microbiocides | |
| CL2009001151A1 (es) | Compuestos derivados de acidos carbociclicos aliciclicos de benzomorfanos, procedimiento de preparacion, composicion farmaceutica, utiles para tratar enfermedades influenciadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa, como trastornos metabolicos. | |
| UY32125A (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CL2011001947A1 (es) | Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular. | |
| MX368459B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| WO2011132051A3 (en) | Tricycle compounds as phosphodiesterase-10 inhibitors | |
| GEP20135959B (en) | Aryl piperazine and their usage as alpha2c antagonists | |
| WO2007100777A3 (en) | Methods for the treatment of adhd and related disorders | |
| WO2009037542A3 (en) | Spirocyclic compounds as stearoyl coa desaturase inhibitors | |
| CL2008001837A1 (es) | Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia. | |
| GB201114389D0 (en) | Novel compounds | |
| PH12014502780A1 (en) | Azetidine and piperidine compounds useful as pde10 inhibitors | |
| NZ609924A (en) | Porphyrin treatment of neurodegenerative diseases | |
| WO2010024911A8 (en) | Methods for increasing neurogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |